WHO and UNICEF urge donors and member states to fund and expand use of vaccine vial monitors to ensure effective immunization

in page functions

Two billion heat-sensitive vaccine monitors used over last decade

Geneva 3 May 2007 - The World Health Organization (WHO) and UNICEF announce today a new joint policy statement on the role of vaccine vial monitors (VVMs) in improving access to immunization, on the 10-year anniversary of introduction of VVMs in immunization programmes.

A VVM is a simple tool which clearly warns if a vaccine is likely to have been damaged by heat. Its use over the last ten years has made it possible for more children in more places to have access to vaccine.

It is a circular indicator, printed directly on a vaccine vial label or affixed to the top of the vial or ampoule. The inner square of the monitor is made of heat-sensitive material that is light in colour but becomes darker when exposed to heat, indicating to health workers that the vaccine may no longer be effective.

"Handling vaccines requires great care. All vaccines are sensitive to heat and some to freezing. Vaccine vial monitors are useful tools for detection of the vaccine's exposure to excessive temperature, thus contributing to success of immunization programmes," said Mrs Daisy Mafubelu, Assistant Director-General of the Family and Community Health Cluster, WHO.

For example, during the May 2006 earthquake in Yogyakarta, Indonesia, much of the infrastructure was damaged including the refrigeration facilities at the health centres. Normally, unrefrigerated vaccines would need to be discarded. In this case, by observing the monitors on the vaccine vials, health workers were able to see that the vaccines were still usable. In total, up to 50 000 doses of various vaccines were saved from being wasted thanks to VVMs.

Since their introduction in 1996, nearly 2 billion monitors have been used on vaccine vials. WHO and UNICEF estimate that the use of VVMs is saving the global health community at least US$ 5 million per year. Over the next 10 years, the monitors will allow health workers to recognize and replace more than 230 million doses of unusable vaccines.

The new WHO/UNICEF joint policy statement urges all vaccine self-procuring countries to include the vaccine vial monitors among the minimum requirements for vaccine purchase agreements. It also urges all donor agencies and international non-governmental organizations to adopt a policy that explicitly includes vaccine vial monitors as a minimum standard in every vaccine donation.

In marking the 10th Anniversary, the GAVI Alliance Deputy Executive Secretary Michel Zaffran said: "Since their introduction ten years ago, vaccine vial monitors have played a crucial role in overcoming challenges related to safe delivery of vaccines, especially in hot climates where vaccine refrigeration is weak or inexistent. GAVI has consistently supported the inclusion of VVMs with the vaccines it funds, and we urge all vaccine manufacturers to ensure all their products be delivered with vaccine vial monitor technology included. We are confident that the GAVI requirement that all new vaccines be fitted with monitors has helped move this important agenda forward."

The VVM concept was developed in 1979 by WHO and PATH, with funding from the United States Agency for International Development. Temptime Corporation (formerly Lifelines Inc.) today provides VVMs to all vaccine manufacturers. In 1996, the first monitors became available on oral polio vaccine, adding only a few cents to the price of each vial. PATH and WHO have developed and tested training materials for health workers that help them learn how to handle vaccines and use the monitors effectively.

Today, more than 100 participants representing governments, vaccine manufacturers, institutions, organizations and donor agencies, as well as the media, will participate in the 10th anniversary celebration at WHO. Together with the event, a photo exhibition entitled Five Senses will be opened in the hall of the main WHO building.

+ 150 million

By the end of 2013, 11 countries in the African meningitis belt had collectively immunised 153 million people against meningitis A with support from the Vaccine Alliance.

WHO/UNICEF

More facts...

close icon

modal window here